Ameriprise’s Tango Therapeutics TNGX Stock Holding History

Ameriprise’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.58M	Sell	306,345 -199,813	-39%	-$4.94M	﹤0.01%	2088
2026 Q1	$10.6M	Buy	+506,158	New	+$7.05M	﹤0.01%	1882
2025 Q2	–	Sell	-82,657	Closed	-$113K	–	4125
2025 Q1	$113K	Buy	82,657 +71,459	+638%	+$176K	﹤0.01%	3865
2024 Q4	$34.6K	Buy	+11,198	New	+$52K	﹤0.01%	4029
2023 Q4	–	Sell	-12,715	Closed	-$143K	–	3977
2023 Q3	$143K	Sell	12,715 -38,544	-75%	-$235K	﹤0.01%	3744
2023 Q2	$170K	Sell	51,259 -1,185	-2%	-$4.26K	﹤0.01%	3750
2023 Q1	$207K	Buy	52,444 +24,434	+87%	+$142K	﹤0.01%	3722
2022 Q4	$203K	Buy	28,010 +10	+0%	+$70	﹤0.01%	3701
2022 Q3	$101K	Buy	+28,000	New	+$120K	﹤0.01%	3829

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Ameriprise's TNGX Position: Q2 2026 in Review

Ameriprise reduced its Tango Therapeutics (TNGX) stake by 39% in Q2 2026, selling an estimated $4.94M and leaving 306,345 shares worth $9.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

Ameriprise first reported a position in TNGX in Q3 2022 and has held it in 9 quarters since. The position peaked at $10.6M in Q1 2026. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

Ameriprise held 306,345 shares of Tango Therapeutics worth $9.58M as of Q2 2026.
Ameriprise sold 199,813 Tango Therapeutics shares in Q2 2026, an estimated $4.94M.
Tango Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2088 holding.
Ameriprise first reported a position in Tango Therapeutics in Q3 2022 and has held it in 9 quarters since.
Ameriprise's Tango Therapeutics position peaked at $10.6M in Q1 2026.
248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.